- Home
- LVLU vs COCP Comparison
LVLU vs COCP Comparison
Compare LVLU & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- COCP
- Stock Information
- Founded
- LVLU 1996
- COCP 2006
- Country
- LVLU United States
- COCP United States
- Employees
- LVLU N/A
- COCP N/A
- Industry
- LVLU Catalog/Specialty Distribution
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- COCP Health Care
- Exchange
- LVLU Nasdaq
- COCP Nasdaq
- Market Cap
- LVLU 18.4M
- COCP 15.4M
- IPO Year
- LVLU 2021
- COCP N/A
- Fundamental
- Price
- LVLU $4.28
- COCP $1.64
- Analyst Decision
- LVLU Hold
- COCP Strong Buy
- Analyst Count
- LVLU 2
- COCP 1
- Target Price
- LVLU $15.00
- COCP $6.00
- AVG Volume (30 Days)
- LVLU 113.6K
- COCP 27.6K
- Earning Date
- LVLU 08-13-2025
- COCP 08-13-2025
- Dividend Yield
- LVLU N/A
- COCP N/A
- EPS Growth
- LVLU N/A
- COCP N/A
- EPS
- LVLU N/A
- COCP N/A
- Revenue
- LVLU $302,783,000.00
- COCP N/A
- Revenue This Year
- LVLU N/A
- COCP N/A
- Revenue Next Year
- LVLU $2.53
- COCP N/A
- P/E Ratio
- LVLU N/A
- COCP N/A
- Revenue Growth
- LVLU N/A
- COCP N/A
- 52 Week Low
- LVLU $3.30
- COCP $1.12
- 52 Week High
- LVLU $28.05
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- LVLU 39.31
- COCP 55.46
- Support Level
- LVLU $4.15
- COCP $1.61
- Resistance Level
- LVLU $5.80
- COCP $1.81
- Average True Range (ATR)
- LVLU 1.14
- COCP 0.11
- MACD
- LVLU 0.02
- COCP 0.01
- Stochastic Oscillator
- LVLU 16.76
- COCP 43.14
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).